At the 67th American Society of Hematology (ASH) Annual Meeting, researchers from The University of Texas MD Anderson Cancer Center presented new clinical data positioning pivekimab sunirine (PVEK), a CD123-targeting antibody-drug conjugate, as a potential addition to treatment strategies for two aggressive and historically hard-to-treat malignancies: acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Unlike many antibodies that rely solely on immune engagement, PVEK delivers a DNA-damaging payload directly into CD123-expressing cells, a design intended to support activity even in chemoresistant disease.

A targeted strategy for CD123-positive leukemias

The first study , a Phase Ib/II trial led by Naval Daver, MD, explored whether PVEK could enhance

See Full Page